Project: Effective Treatment for sporadic inclusion body myositis (sIBM)
The objective of the project is to deliver a commercially available treatment for Sporadic Inclusion-body Myositis (sIBM) – a progressively disabling muscle disease with currently no effective treatment. The result is the first available disease-modifying drug on the market. We will do this by monitoring a phase III clinical trial verifying the efficacy of the compound arimoclomol in patients to ensure that the quality of the trial data corresponds with the expectations of authorities.
Acronym | TREAT-sIBM (Reference Number: 10533) |
Duration | 01/07/2016 - 01/07/2019 |
Project Topic | Biological Sciences / Technologies |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 5 |